Clinical Trial Update: Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates rituximab and pembrolizumab with or without lenalidomide in relapsed follicular lymphoma and diffuse large B-cell lymphoma, with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Pembrolizumab (pembrolizumab)
• Rituximab (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-02-27